Personalized Skin Cancer Vaccine Shows Promising Results in Halving Risk of Death or Recurrence

A world-first personalized skin cancer vaccine has shown promising results, slashing the risk of death or cancer returning by nearly half in patients with deadly melanoma. The vaccine, named Intisomeran, utilizes mRNA technology similar to that used in COVID-19 vaccines and has demonstrated its potential to usher in a new era of disease fighting.

Melanoma, one of the most aggressive forms of skin cancer, affects approximately 21,000 people annually in the UK alone. For patients whose cancer has spread to nearby lymph nodes or distant organs, the five-year survival rate is only 40 percent.

Clinical Trial Findings

Results from a phase three clinical trial, set to be presented at the European Society of Medical Oncology (ESMO) conference in Madrid, revealed that the personalized vaccine, when administered alongside immunotherapy, reduced the risk of melanoma spreading by 38 percent over two years compared to immunotherapy alone. The trial involved 1,137 patients who had their cancer surgically removed but were at high risk of recurrence.

All participants received a year of the immunotherapy drug pembrolizumab, which helps the immune system target cancer cells. However, cancer cells can develop resistance to immunotherapy, prompting research into complementary treatments like vaccines. Of the trial participants, two-thirds received Intisomeran, while the remainder received a placebo.

Intisomeran is tailored to each patient by analyzing their individual tumors. This process trains the patient's immune system to better identify and target cancer cells should they reappear. The trial, led by researchers at the Melanoma Institute Australia, found that at two years post-treatment, patients who received the vaccine were 42 percent less likely to experience cancer recurrence or metastasis to other organs. This means that for every 100 patients treated, an additional 12 were alive and cancer-free two years after the initial treatment.

Side Effects and Future Prospects

While the vaccine shows significant benefits, approximately six additional patients per 100 experienced treatment-related side effects, including fever, fatigue, and reactions at the injection site. Experts note that while the results are encouraging, approximately nine patients need to be treated to prevent one additional recurrence or death over the two-year period.

Researchers are optimistic that melanoma treatments are leading the way for similar vaccines being investigated for other cancers, including those that are difficult to treat and do not respond well to current immune-based therapies. The primary challenge now lies in identifying which cancers and patients are most likely to benefit and determining the optimal vaccine targets.

Drug manufacturers MSD and Moderna are already testing this approach against other types of tumors, including kidney, bladder, and lung cancer, with hopes of filing for regulatory approval as early as next year. However, the widespread adoption by healthcare systems like the NHS will depend on cost-effectiveness, given that each vaccine requires individual tumor profiling.

The ongoing trial will continue to monitor patients to assess long-term outcomes and the vaccine's ultimate impact on survival rates. Experts emphasize that while this represents a significant proof of principle, true breakthroughs will be achieved when all patients can benefit equally, making the treatment practically achievable and affordable for everyone affected by cancer.